[go: up one dir, main page]

CL2018003013A1 - Uso de un inhibidor de la acetilcolinesterasa e idalopirdina para reducir las caídas en pacientes con la enfermedad de parkinson. - Google Patents

Uso de un inhibidor de la acetilcolinesterasa e idalopirdina para reducir las caídas en pacientes con la enfermedad de parkinson.

Info

Publication number
CL2018003013A1
CL2018003013A1 CL2018003013A CL2018003013A CL2018003013A1 CL 2018003013 A1 CL2018003013 A1 CL 2018003013A1 CL 2018003013 A CL2018003013 A CL 2018003013A CL 2018003013 A CL2018003013 A CL 2018003013A CL 2018003013 A1 CL2018003013 A1 CL 2018003013A1
Authority
CL
Chile
Prior art keywords
patients
disease
idalopirdine
parkinson
inhibitor
Prior art date
Application number
CL2018003013A
Other languages
English (en)
Inventor
Jong Inge E M De
Aaron Kucinski
Martir Sarter
Original Assignee
H Lundbeck As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by H Lundbeck As filed Critical H Lundbeck As
Publication of CL2018003013A1 publication Critical patent/CL2018003013A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

LA PRESENTE INVENCIÓN SE REFIERE AL USO DE UN INHIBIDOR DE LA ACETILCOLINESTERASA E IDALOPIRDINA PARA REDUCIR LAS CAÍDAS EN PACIENTES QUE PADECEN UNA ENFERMEDAD DEL CNS, EN PARTICULAR EN PACIENTES CON LA ENFERMEDAD DE PARKINSON, EN LA QUE SE DETERIORAN EL EQUILIBRIO, LA MARCHA O EL MOVIMIENTO.
CL2018003013A 2016-04-26 2018-10-24 Uso de un inhibidor de la acetilcolinesterasa e idalopirdina para reducir las caídas en pacientes con la enfermedad de parkinson. CL2018003013A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DKPA201600248 2016-04-26

Publications (1)

Publication Number Publication Date
CL2018003013A1 true CL2018003013A1 (es) 2018-12-14

Family

ID=58632402

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2018003013A CL2018003013A1 (es) 2016-04-26 2018-10-24 Uso de un inhibidor de la acetilcolinesterasa e idalopirdina para reducir las caídas en pacientes con la enfermedad de parkinson.

Country Status (28)

Country Link
US (1) US10383849B2 (es)
EP (1) EP3448430B1 (es)
JP (1) JP6992004B2 (es)
KR (1) KR102473545B1 (es)
CN (3) CN118806910A (es)
AU (1) AU2017256623B2 (es)
BR (1) BR112017026928B1 (es)
CA (1) CA3020557C (es)
CL (1) CL2018003013A1 (es)
CY (1) CY1126138T1 (es)
DK (1) DK3448430T3 (es)
ES (1) ES2949288T3 (es)
FI (1) FI3448430T3 (es)
HR (1) HRP20230693T8 (es)
HU (1) HUE062626T2 (es)
IL (1) IL262546B (es)
LT (1) LT3448430T (es)
MX (1) MX387444B (es)
PL (1) PL3448430T3 (es)
PT (1) PT3448430T (es)
RS (1) RS64307B1 (es)
RU (1) RU2742173C2 (es)
SG (1) SG11201809297UA (es)
SI (1) SI3448430T1 (es)
SM (1) SMT202300197T1 (es)
TW (1) TW201806621A (es)
WO (1) WO2017186686A1 (es)
ZA (1) ZA201806864B (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2869128T3 (es) * 2017-05-24 2021-10-25 H Lundbeck As Combinación de un antagonista de receptor 5-HT6 y un inhibidor de acetilcolinesterasa para uso en el tratamiento de la enfermedad de Alzheimer en una subpoblación de pacientes portadores de alelos ApoE4
JP7681884B2 (ja) * 2017-12-22 2025-05-23 ゴールデン ゲイト バイオテック エス エル 神経変性疾患における転倒および転倒頻度に関連する処置のための組成物および方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9818914D0 (en) * 1998-08-28 1998-10-21 Smithkline Beecham Plc Use
PT1859798E (pt) * 2001-03-29 2016-03-31 Lilly Co Eli N-(2-ariletil)benzilaminas como antagonistas do receptor 5-ht6
EP1871368B1 (en) * 2005-04-04 2011-06-08 Eisai R&D Management Co., Ltd. Dihydropyridine compounds for neurodegenerative diseases and dementia
PE20071143A1 (es) * 2006-01-13 2008-01-20 Wyeth Corp Composicion farmaceutica que comprende un inhibidor de acetilcolinesterasa y un antagonista 5-hidroxitriptamina-6
CN101500611A (zh) * 2006-06-23 2009-08-05 埃斯蒂维实验室股份有限公司 胆碱脂酶抑制剂与具有5-ht6受体亲和力的化合物的组合
EP2508177A1 (en) * 2007-12-12 2012-10-10 Glaxo Group Limited Combinations comprising 3-phenylsulfonyl-8-piperazinyl-1yl-quinoline
RU2393158C1 (ru) * 2008-10-06 2010-06-27 Андрей Александрович Иващенко ЗАМЕЩЕННЫЕ 3-АРИЛСУЛЬФОНИЛ-ПИРАЗОЛО[1,5-а]ПИРИМИДИНЫ, АНТАГОНИСТЫ СЕРОТОНИНОВЫХ 5-HT6 РЕЦЕПТОРОВ, СПОСОБЫ ИХ ПОЛУЧЕНИЯ И ПРИМЕНЕНИЯ
JO3459B1 (ar) * 2012-09-09 2020-07-05 H Lundbeck As تركيبات صيدلانية لعلاج مرض الزهايمر

Also Published As

Publication number Publication date
DK3448430T3 (da) 2023-07-03
CY1126138T1 (el) 2023-11-15
MX387444B (es) 2025-03-18
ES2949288T3 (es) 2023-09-27
PL3448430T3 (pl) 2023-08-21
CN118806909A (zh) 2024-10-22
CA3020557C (en) 2024-05-21
CN109069650A (zh) 2018-12-21
CA3020557A1 (en) 2017-11-02
JP2019519480A (ja) 2019-07-11
FI3448430T3 (fi) 2023-06-20
LT3448430T (lt) 2023-07-25
RU2018135846A3 (es) 2020-09-30
KR102473545B1 (ko) 2022-12-01
IL262546B (en) 2022-05-01
TW201806621A (zh) 2018-03-01
RU2018135846A (ru) 2020-05-26
HUE062626T2 (hu) 2023-11-28
AU2017256623B2 (en) 2022-07-21
SMT202300197T1 (it) 2023-09-06
RU2742173C2 (ru) 2021-02-02
RS64307B1 (sr) 2023-07-31
MX2018013031A (es) 2019-01-17
EP3448430B1 (en) 2023-06-07
IL262546A (en) 2018-12-31
EP3448430A1 (en) 2019-03-06
WO2017186686A1 (en) 2017-11-02
CN118806910A (zh) 2024-10-22
HRP20230693T8 (hr) 2023-11-10
US20170304267A1 (en) 2017-10-26
BR112017026928B1 (pt) 2023-04-11
AU2017256623A1 (en) 2018-11-01
JP6992004B2 (ja) 2022-02-03
SI3448430T1 (sl) 2023-08-31
KR20180133869A (ko) 2018-12-17
US10383849B2 (en) 2019-08-20
PT3448430T (pt) 2023-07-11
ZA201806864B (en) 2020-01-29
HRP20230693T1 (hr) 2023-10-13
BR112017026928A2 (pt) 2018-08-14
SG11201809297UA (en) 2018-11-29

Similar Documents

Publication Publication Date Title
DOP2019000180A (es) INHIBIDORES DE TGFß1 ISOFORMA-ESPECÍFICOS CONTEXTO-PERMISIVOS Y USO DE LOS MISMOS
ECSP19015192A (es) Composiciones y métodos de inhibir masp-3 para el tratamiento de diversas enfermedades y trastornos
CL2019003144A1 (es) Formulaciones de anticuerpos anti-lag3 y co-formulaciones de anticuerpos anti-lag3 y anticuerpos anti-pd-1.
CO2017013443A2 (es) Composiciones que comprenden cepas bacterianas del género blautia
CL2018001349A1 (es) Composiciones que comprenden cepas bacterianas
CL2018001367A1 (es) Composiciones que comprenden cepas bacterianas
AR111208A1 (es) ANTICUERPOS ANTI-PÉPTIDO b AMILOIDE N3PGLU Y SUS USOS
PE20180267A1 (es) Composiciones que comprenden cepas bacterianas
CO2017013446A2 (es) Composiciones que comprenden cepas bacterianas del género bacteroides
CL2018002698A1 (es) Tratamiento de enfermedades inflamatorias con inhibidores de actividad c5a
CO2017004525A2 (es) Dihidropirrolopiridinas inhibidoras de ror-gamma
UY38003A (es) Construcciones de arni para inhibir la expresión de pnpla3 y métodos de uso de las mismas
UY36224A (es) Compuestos tricíclicos de imidazo-pirimidinona
MX2017001279A (es) Usos y composiciones de la flagelina.
CL2018000597A1 (es) Métodos para tratar enfermedades inflamatorias
MX380252B (es) Crenezumab para usarse en el tratamiento de enfermedad de alzheimer.
MX377663B (es) Intermediarios en la sintesis de eribulina y metodos de sintesis relacionados.
CL2019002733A1 (es) Formulaciones de clorhidrato del ácido 1-amino-1-ciclopropanocarboxílico.
BR112018069682A2 (pt) métodos de tratamento para doenças colestáticas e fibróticas
MX392754B (es) Seleccion de cepas bacterianas utiles en el tratamiento de la alergia.
CO2019004131A2 (es) Glicinato de metformina, composiciones farmacéuticas que comprenden la misma, y métodos de uso de la misma
DOP2017000014A (es) Métodos para mejorar el rendimiento miocárdico en pacientes con cirugía de fontan que utilizan composiciones de udenafilo
MX392976B (es) Composiciones que comprenden cepas bacterianas.
CL2021000930A1 (es) Piridazinas novedosas
MX2017003469A (es) Inhibidores macrociclicos de cinasa rip2.